z-logo
open-access-imgOpen Access
Development and evaluation of murine lung-specific disease models for Pseudomonas aeruginosa applicable to therapeutic testing
Author(s) -
Matthew B. Lawrenz,
Ashley E. Biller,
Daniel Cramer,
Jennifer Kraenzle,
Julie Sotsky,
Carol D. Vanover,
Deborah R. Yoder-Himes,
Angela Pollard,
Jonathan M. Warawa
Publication year - 2015
Publication title -
pathogens and disease
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.983
H-Index - 105
ISSN - 2049-632X
DOI - 10.1093/femspd/ftv025
Subject(s) - pseudomonas aeruginosa , pneumonia , meropenem , medicine , disease , pathogen , microbiology and biotechnology , biology , antibiotics , immunology , antibiotic resistance , bacteria , pathology , genetics
Pseudomonas aeruginosa is an opportunistic bacterial pathogen capable of causing a wide range of disease manifestations, including severe bacterial pneumonia. Recently, clinics have reported a rise in nosocomial infections with multidrug resistant (MDR) species, including MDR strains of P. aeruginosa. In order to quickly evaluate the efficacy of new therapeutics for MDR infections, highly reproducible and validated animal models need to be developed for pre-clinical testing. Here, we describe the characterization of two murine models to study MDR P. aeruginosa respiratory disease. We evaluated and compared these models using a non-invasive intratracheal instillation method and established the 50% lethal dose, course of infection, biometric parameters of disease and degree of pneumonia development for each model. Further, we tested meropenem as a proof-of-concept therapeutic and report efficacy data that suggests that the leukopenic model could serve a robust pre-clinical model to test novel therapeutics.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom